Eli Lilly sanguine about China market

Eli Lilly logo is shown on one of the company's offices in San Diego, California, US, Sept 17, 2020. Eli Lilly said people who are overweight or those who face obesity issues face social stigma every day and that the drugmaker aims to improve the quality of their lives. "The commonly held view that their weight is somehow their own fault, or their individual responsibility, is one of the biggest barriers preventing people who are overweight or with obesity from accessing the healthcare they need," said Huzur Devletsah, president and general manager of Lilly China. "In the past five years, only 54 percent of overweight and obese individuals in China discussed weight management with doctors, and many experienced delayed medical treatment," said Qu Shen, director of the obesity research institute of Tongji University School of Medicine. In July, the National Medical Products Administration approved tirzepatide injections for chronic weight management, a prescription medication for adults developed by Eli Lilly that is not intended for cosmetic use.